Pharming Reports on Extraordinary General Meeting

Pharming Reports on Extraordinary General Meeting 
LEIDEN, THE NETHERLANDS -- (Marketwire) -- 02/28/13 --  Biotech
company Pharming Group NV ("Pharming" or  "the  Company")  (NYSE 
Euronext: PHARM) announced that at its Extraordinary  General Meeting
(EGM) of  shareholders, held today, all proposals were approved,
including an amendment of its articles of association effecting a
10:1 reverse  share split and a  reduction of the nominal  value of
the combined shares. 
Pursuant to the reverse share split, every ten shares of Pharming
with a nominal value  of EUR 0.01 each will be combined into  one
share with a nominal value of EUR  0.10 each, and the nominal value
of these new shares will be reduced to EUR 0.01 each. 
Trading  in the new shares with ISIN  Code NL0010391025 will start on
Tuesday 5 March 2013. No actions from shareholders are required. 
Following  the  reverse  share  split,  Pharming  will have
approximately 118.9 million shares outstanding with a nominal value of
EUR 0.01 each. 
Any  shareholders that have specific questions on the reverse share
split should contact their account bank. 
About Pharming Group NV 
Pharming Group NV is developing innovative products for the treatment
of unmet medical needs. RUCONEST(R) is a recombinant human C1
inhibitor approved for the treatment of angioedema attacks in patients
with HAE in all 27 EU countries plus Norway, Iceland and
Liechtenstein, and is distributed in the EU by Swedish Orphan
Biovitrum. RUCONEST(R) is partnered with Santarus Inc (NASDAQ: SNTS)
in North America where the drug has completed Phase III clinical
development. The product is also being evaluated for various
follow-on indications. Pharming has a unique GMP compliant, validated
rabbit platform for the production of recombinant human proteins
that, with the EU approval of Pharming's rhC1 inhibitor, has proven
capable of producing industrial volumes of high quality recombinant
human protein in a significantly more economical way through low
upfront capital investment and manufacturing costs, compared to
current cell based technologies. Pharming now plans to utilise this
platform for the development of rhFVIII for the treatment of
Haemophilia A. 
Additional information is available on the Pharming website, 
This  press release contains  forward looking statements  that
involve known and unknown  risks,  uncertainties  and  other  factors,
 which may cause the actual results,  performance or achievements of
the  Company to be materially different from  the results, 
performance or  achievements expressed  or implied  by these forward
looking statements. 
Press release (PDF): 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and
other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein. 
Source: Pharming Group N.V. via Thomson Reuters ONE 
Sijmen de Vries
T: +31 524 7400
Press spacebar to pause and continue. Press esc to stop.